Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria-Reference-Cited by-同舟云学术

Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria

Published:2022-02-23 Issue:1 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Deng Tian¹,Jia Yuqian¹,Tong Ziwen¹,Shi Jingru¹,Wang Zhiqiang¹²^ORCID,Liu Yuan¹²³^ORCID

Affiliation:

1. College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, China

2. Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Joint International Research Laboratory of Agriculture and Agri-Product Safety, the Ministry of Education of China, Yangzhou University, Yangzhou, Jiangsu, China

3. Institute of Comparative Medicine, Yangzhou University, Yangzhou, Jiangsu, China

Abstract

Recently, high-level tigecycline resistance mediated by tet (X4) and its variants represents a serious challenge for global public health. Antibiotic adjuvant strategy that enhances the activity of the existing antibiotics by using nonantibiotic drugs offers a distinct approach to combat the antibiotic resistance crisis. In this study, we found that bismuth drugs involve bismuth nitrate, a compound previously approved for treatment of stomach-associated diseases, remarkably potentiates tigecycline activity against tet (X)-positive bacteria.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Jiangsu Agricultural Science and Technology Independent Innovation Fund

Priority Academic Program Development of Jiangsu Higher Education Institutions

National Key Research and Development Program of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01578-21